NEA Management Company’s Regulus Therapeutics RGLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-6,467,802
| Closed | -$11.3M | – | 36 |
|
|
2025
Q1 | $11.3M | Hold |
6,467,802
| – | – | 0.87% | 22 |
|
|
2024
Q4 | $10.2M | Hold |
6,467,802
| – | – | 0.58% | 24 |
|
|
2024
Q3 | $10.2M | Hold |
6,467,802
| – | – | 0.55% | 27 |
|
|
2024
Q2 | $11.6M | Hold |
6,467,802
| – | – | 0.87% | 22 |
|
|
2024
Q1 | $18.6M | Buy |
6,467,802
+4,522,223
| +232% | +$7.37M | 1.16% | 24 |
|
|
2023
Q4 | $2.49M | Hold |
1,945,579
| – | – | 0.17% | 38 |
|
|
2023
Q3 | $2.67M | Hold |
1,945,579
| – | – | 0.21% | 36 |
|
|
2023
Q2 | $2.86M | Buy |
1,945,579
+500,465
| +35% | +$667K | 0.22% | 37 |
|
|
2023
Q1 | $1.22M | Hold |
1,445,114
| – | – | 0.08% | 42 |
|
|
2022
Q4 | $1.98M | Sell |
1,445,114
-1
| -0% | -$2 | 0.11% | 49 |
|
|
2022
Q3 | $2.46M | Hold |
1,445,115
| – | – | 0.12% | 50 |
|
|
2022
Q2 | $2.99M | Hold |
1,445,115
| – | – | 0.15% | 51 |
|
|
2022
Q1 | $4.31M | Buy |
1,445,115
+800,009
| +124% | +$2.08M | 0.12% | 52 |
|
|
2021
Q4 | $2.06M | Hold |
645,106
| – | – | 0.04% | 54 |
|
|
2021
Q3 | $4.46M | Hold |
645,106
| – | – | 0.05% | 57 |
|
|
2021
Q2 | $5.22M | Hold |
645,106
| – | – | 0.07% | 57 |
|
|
2021
Q1 | $10.1M | Hold |
645,106
| – | – | 0.23% | 50 |
|
|
2020
Q4 | $8.71M | Buy |
645,106
+439,860
| +214% | +$3.23M | 0.23% | 47 |
|
|
2020
Q3 | $1.05M | Hold |
205,246
| – | – | 0.04% | 50 |
|
|
2020
Q2 | $1.4M | Hold |
205,246
| – | – | 0.06% | 43 |
|
|
2020
Q1 | $946K | Hold |
205,246
| – | – | 0.05% | 46 |
|
|
2019
Q4 | $1.83M | Hold |
205,246
| – | – | 0.09% | 43 |
|
|
2019
Q3 | $1.48M | Hold |
205,246
| – | – | 0.12% | 41 |
|
|
2019
Q2 | $2.57M | Buy |
205,246
+113,671
| +124% | +$1.31M | 0.18% | 37 |
|
|
2019
Q1 | $934K | Hold |
91,575
| – | – | 0.05% | 45 |
|
|
2018
Q4 | $852K | Hold |
91,575
| – | – | 0.03% | 44 |
|
|
2018
Q3 | $26M | Sell |
91,575
-8
| -0% | -$264 | 1.12% | 21 |
|
|
2018
Q2 | $7.24M | Hold |
91,583
| – | – | 0.34% | 37 |
|
|
2018
Q1 | $7.88M | Hold |
91,583
| – | – | 0.35% | 35 |
|
|
2017
Q4 | $11.4M | Hold |
91,583
| – | – | 0.47% | 29 |
|
|
2017
Q3 | $13.7M | Buy |
+91,583
| New | +$11.5M | 0.48% | 25 |
|
Other funds holding RGLS
NEA Management Company's RGLS Position: Q2 2025 in Review
NEA Management Company sold out of Regulus Therapeutics (RGLS) in Q2 2025, closing a stake of 6,467,802 shares — an estimated $11.3M sold.
NEA Management Company first reported a position in RGLS in Q3 2017 and held it in 31 quarters. The position peaked at $26M in Q3 2018. 0 funds tracked by Wall St. Rank hold RGLS as of Q2 2025.
- NEA Management Company reported no remaining Regulus Therapeutics position as of Q2 2025 after selling out during the quarter.
- NEA Management Company sold 6,467,802 Regulus Therapeutics shares in Q2 2025, an estimated $11.3M.
- NEA Management Company first reported a position in Regulus Therapeutics in Q3 2017 and held it in 31 quarters.
- NEA Management Company's Regulus Therapeutics position peaked at $26M in Q3 2018.
- 0 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2025.
Based on NEA Management Company's 13F filing for Q2 2025, filed 14 Aug 2025.